-transparent.png){kind=logo}
OBJECTIVE Recombinant viral vectors based on the nonpathogenic parvovirus, adeno-associated virus (AAV), have a number of attractive features for gene therapy, including the ability to transduce non-dividing cells and its long-term transgene expression. In this study, an AAV vector containing bacterial beta-galactosidase gene (lacZ) was used to transduce cultured rat vascular smooth muscle cells (VSMC) in vitro and rat thoracic aortas ex vivo. METHODS VSMC were transduced with AAV-lacZ at multiplicities of infection (MOI) ranging from 5.0 x 10(5) to 1.0 x 10(7). Expression of beta-galactosidase (beta-gal) in VSMC was evaluated by X-gal staining and a beta-gal ELISA method. Excised rat aortas were incubated with medium containing AAV-lacZ. Expression of beta-gal in the aortic segments was evaluated by X-gal staining. RESULTS With increasing MOI, up to 50% of cultured VSMC were positive by X-gal staining and the beta-gal expression increased up to 15 ng/mg protein. The expression gradually decreased during the culture but was detectable for at least 1 month. In the ex vivo study, AAV vectors transduced endothelial and adventitial cells in rat aortic segments, while no expression was seen in medial VSMC. CONCLUSIONS AAV vectors can efficiently transduce rat VSMC in vitro. AAV-mediated ex vivo gene transfer into the normal aorta resulted in efficient gene transfer into endothelial and adventitial cells but not into medial VSMC. These findings suggest that AAV-based vectors are promising for use in cardiovascular gene therapy.
Y Maeda, and
U Ikeda, and
Y Ogasawara, and
M Urabe, and
T Takizawa, and
T Saito, and
P Colosi, and
G Kurtzman, and
K Shimada, and
K Ozawa
August 1997,
Nihon rinsho. Japanese journal of clinical medicine,
Y Maeda, and
U Ikeda, and
Y Ogasawara, and
M Urabe, and
T Takizawa, and
T Saito, and
P Colosi, and
G Kurtzman, and
K Shimada, and
K Ozawa
December 2003,
Uirusu,
Y Maeda, and
U Ikeda, and
Y Ogasawara, and
M Urabe, and
T Takizawa, and
T Saito, and
P Colosi, and
G Kurtzman, and
K Shimada, and
K Ozawa
January 1996,
Current topics in microbiology and immunology,
Y Maeda, and
U Ikeda, and
Y Ogasawara, and
M Urabe, and
T Takizawa, and
T Saito, and
P Colosi, and
G Kurtzman, and
K Shimada, and
K Ozawa
May 2023,
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,
Y Maeda, and
U Ikeda, and
Y Ogasawara, and
M Urabe, and
T Takizawa, and
T Saito, and
P Colosi, and
G Kurtzman, and
K Shimada, and
K Ozawa
March 1998,
Nihon rinsho. Japanese journal of clinical medicine,
Y Maeda, and
U Ikeda, and
Y Ogasawara, and
M Urabe, and
T Takizawa, and
T Saito, and
P Colosi, and
G Kurtzman, and
K Shimada, and
K Ozawa
June 2008,
The journal of gene medicine,
Y Maeda, and
U Ikeda, and
Y Ogasawara, and
M Urabe, and
T Takizawa, and
T Saito, and
P Colosi, and
G Kurtzman, and
K Shimada, and
K Ozawa
December 1995,
Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
Y Maeda, and
U Ikeda, and
Y Ogasawara, and
M Urabe, and
T Takizawa, and
T Saito, and
P Colosi, and
G Kurtzman, and
K Shimada, and
K Ozawa
January 2000,
Journal of neural transmission. Supplementum,
Y Maeda, and
U Ikeda, and
Y Ogasawara, and
M Urabe, and
T Takizawa, and
T Saito, and
P Colosi, and
G Kurtzman, and
K Shimada, and
K Ozawa
September 1994,
Journal of virology,
Y Maeda, and
U Ikeda, and
Y Ogasawara, and
M Urabe, and
T Takizawa, and
T Saito, and
P Colosi, and
G Kurtzman, and
K Shimada, and
K Ozawa
July 2001,
Hypertension research : official journal of the Japanese Society of Hypertension,
